DMR-001 not checked

Damora Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“DMR-001 will be administered at protocol defined dose at a frequency of every 4 weeks.”In the company’s words, NCT07849231 on ClinicalTrials.gov
Tested for
Myeloproliferative Neoplasms (MPNs)
Main trialPhase 1
“This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.”In the company’s words, NCT07849231 on ClinicalTrials.gov

Other drugs for Myeloproliferative Neoplasms (MPNs)

All 67 drugs for Myeloproliferative Neoplasms (MPNs)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Jun 2030 A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow DMR-001

Following is part of Solo: you see every change to DMR-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in